Abstract: Described is a labeling technique which can facilitate the metabolism in the liver after administration to patients without the reduction in the antibody function, thereby reducing accumulation of radionuclides in an organ such as the liver, and a modified antibody containing an IgG antibody and an IgG-binding peptide bound to the IgG antibody. The IgG-binding peptide has an amino acid sequence consisting of 13 to 17 amino acid residues, such as GPDCAYH(Xaa1)GELVWCTFH (SEQ ID NO: 2) wherein Xaa1 represents a lysine residue, a cysteine residue, an aspartic acid residue, a glutamic acid residue, 2-aminosuberic acid, or diaminopropionic acid, and a compound represented by the following formula (II-1) is linked at a position of the lysine residue via a modification linker to the N terminus of the IgG-binding peptide.

Abstract: Described are: [1] a compound or the like represented by the formula (1); [2] a compound or the like having a target molecule recognition element bound to the compound or the like described in the above [1]; and [3] a metal complex compound or the like having a metal selected from the group consisting of a radioactive metal and a radioactive atom-labeled metal, and the compound or the like described in the above [1] or [2] coordinated to the metal. Also described are uses of the compound or the like described in the above [1] or [2] or the metal complex compound or the like described in the above [3] in a radioactive drug, a radiotherapeutic agent or a radioactive diagnostic imaging agent.

Abstract: The present invention relates to a labeling technique which can facilitate the metabolism in the liver after administration to patients without the reduction in the antibody function, thereby reducing accumulation of radionuclides in an organ such as the liver, and provides a modified antibody containing an IgG antibody and an IgG-binding peptide bound to the IgG antibody. The IgG-binding peptide has an amino acid sequence consisting of 13 to 17 amino acid residues, such as GPDCAYH(Xaa1)GELVWCTFH wherein Xaa1 represents a lysine residue, a cysteine residue, an aspartic acid residue, a glutamic acid residue, 2-aminosuberic acid, or diaminopropionic acid, and a compound represented by the following formula (II-1) is linked at a position of the lysine residue via a modification linker to the N terminus of the IgG-binding peptide.

Abstract: Described are: [1] a compound represented by the formula (1), [2] a compound containing the compound according to [1] and a target molecule recognition element bonded thereto, [3] a metal complex compound containing one kind of a metal selected from a radioactive metal and a radioactive atom-labeled metal, and the compound according to [1] or [2], which is coordinated to the metal, [4] a drug for preparing a radiolabeled drug, containing the compound according to [1] or [2], [5] use of the compound according to [1] or [2], for producing a radiolabeled drug, [6] a radiolabeled drug containing the metal complex compound according to [3], and [7] a radiodiagnostic imaging agent containing the metal complex compound according to [3]:

Abstract: Described are: [1] a compound or the like represented by the formula (1); [2] a compound or the like having a target molecule recognition element bound to the compound or the like described in the above [1]; and [3] a metal complex compound or the like having a metal selected from the group consisting of a radioactive metal and a radioactive atom-labeled metal, and the compound or the like described in the above [1] or [2] coordinated to the metal. Also described are uses of the compound or the like described in the above [1] or [2] or the metal complex compound or the like described in the above [3] in a radioactive drug, a radiotherapeutic agent or a radioactive diagnostic imaging agent.

Abstract: The present invention relates to a compound, etc. capable of providing a radiolabeled drug that can reduce the renal accumulation thereof in the early stage after the administration thereof. [1] A compound, etc. represented by the formula (1), [2] a compound, etc. containing the compound, etc. according to the item [1] and a target molecule recognition element bonded thereto, [3] a metal complex compound, etc. containing one kind of a metal selected from a radioactive metal and a radioactive atom-labeled metal, and the compound, etc. according to the item [1] or [2], which is coordinated to the metal, [4] a drug for preparing a radiolabeled drug, containing the compound, etc. according to the item [1] or [2], [5] use of the compound, etc. according to the item [1] or [2], for producing a radiolabeled drug, [6] a radiolabeled drug containing the metal complex compound, etc. according to the item [3], and [7] a radiodiagnostic imaging agent containing the metal complex compound, etc.

Abstract: To use 99mTc as a raw material for a radioactive medicine, a very small amount of 99mTc in the high concentration Mo(99Mo) solution is purified and recovered with high yield without contamination of 99Mo. 99mTc with high purity is recovered by forming a high concentration Mo(99Mo) solution which contains radionuclides 99Mo which is the parent nuclide of 99mTc used for the radioactive medicine and the raw material for its labeled compound, forming a high concentration Mo(99Mo) solution which contains radionuclides 99Mo and 99mTc by generating 99mTc to a radioactive-equilibrium state, getting 99mTc in the high concentration Mo(99Mo) solution adsorbed to activated carbon selectively by feeding the solution to an adsorption column which has activated carbon, and undergoing desorption and purification treatment of 99mTc with a desorbent from the activated carbon to which 99mTc is adsorbed.

Abstract: To use 99mTc as a raw material for a radioactive medicine, a very small amount of 99mTc in the high concentration Mo(99Mo) solution is purified and recovered with high yield without contamination of 99Mo. 99mTc with high purity is recovered by forming a high concentration Mo(99Mo) solution which contains radionuclides 99Mo which is the parent nuclide of 99mTc used for the radioactive medicine and the raw material for its labeled compound, forming a high concentration Mo(99Mo) solution which contains radionuclides 99Mo and 99mTc by generating 99mTc to a radioactive-equilibrium state, getting 99mTc in the high concentration Mo(99Mo) solution adsorbed to activated carbon selectively by feeding the solution to an adsorption column which has activated carbon, and undergoing desorption and purification treatment of 99mTc with a desorbent from the activated carbon to which 99mTc is adsorbed.

Abstract: Provided are: a radiolabeled drug, which is efficiently accumulated in a target and has high in vivo stability; and diagnosis and treatment each using the radiolabeled drug. Specifically provided are: a radiolabeled drug showing increased accumulation in a target site, which comprises a complex composed of a ligand that is bound to a compound capable of binding to a target molecule and forms a polycoordinated complex with a metal (e.g., technetium or rhenium) and a radionuclide of the metal; the radiolabeled drug for diagnosis or treatment; a ligand for preparing the radiolabeled drug; a kit that comprises a drug comprising the ligand and a drug comprising a radionuclide of a metal, as separate package units; and a method of increasing accumulation of a radiolabeled drug in a target site, comprising using the above-mentioned radiolabeled drug.

Abstract: An object of the present invention is to provide a method of producing liposome wherein a complex of a short half-life metallic radioactive nuclide such as 99mTc and CD is encapsulated, with radiochemical yield and purity enabling practical application. The present invention provides a method of producing a liposome wherein a complex of a short half-life metallic radioactive nuclide and ethylenedicysteine (CD) is encapsulated, which comprises mixing a complex of a short half-life metallic radioactive nuclide and N-[2-(1H-pyrrolylmethyl)]-N?-(4-penten-3-on-2)-ethane-1,2-diamine with an ethylenedicysteine (CD)-encapsulated liposome, and incubating the mixture.

Abstract: An object of the present invention is to provide a method of producing liposome wherein a complex of a short half-life metallic radioactive nuclide such as 99mTc and CD is encapsulated, with radiochemical yield and purity enabling practical application. The present invention provides a method of producing a liposome wherein a complex of a short half-life metallic radioactive nuclide and ethylenedicysteine (CD) is encapsulated, which comprises mixing a complex of a short half-life metallic radioactive nuclide and N-[2-(1H-pyrrolylmethyl)]-N?-(4-penten-3-on-2)-ethane-1,2-diamine with an ethylenedicysteine (CD)-encapsulated liposome, and incubating the mixture.

Abstract: A Tc-99m mononuclide complex compound of the formula: ##STR1## wherein R.sub.1 and R.sub.2 are each a hydrogen atom or a C.sub.1 -C.sub.3 alkyl group and X is an anion, which is useful as a radioactive diagnostic agent for imaging of brain, cardiac muscle, pancreas or the like.

Abstract: A radioactive diagnostic agent which comprises a physiologically active substance and a radioactive metallic element combined with a compound of the formula: ##STR1## wherein R is a hydrogen atom or a C.sub.1 -C.sub.3 alkyl group and n is an integer of 0 to 4. The agent is characteristic in having a high stability even after being administered into a human body and showing the substantially the same behavior as the physiologically active substance itself in a human body.

Abstract: A radioactive diagnostic agent which comprises a physiologically active substance and a radioactive metallic element combined with a compound of the formula: ##STR1## wherein R, R', R.sup.1 and R.sup.2 are each a hydrogen atom or a C.sub.1 -C.sub.3 alkyl group and n is an integer of 0 to 3. The agent is characteristic in having a high stability even after being administered into a human body and showing the substantially the same behavior as the physiologically active substance itself in a human body.

Abstract: A radioactive diagnostic agent for imaging of various organs, particularly of brain, which comprises a radioactive element such as .sup.

Abstract: A radioactive diagnostic agent which comprises a protein and a radioactive metallic element combined with intervention of a bifunctional chelating agent of the formula: ##STR1## wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are each a hydrogen atom or a C.sub.1 -C.sub.3 alkyl group and is characteristic in having high stability even after administered into a human body.

Abstract: A radioactive diagnostic agent which comprises a protein and a radioactive metallic element combined with intervention of a bifunctional chelating agent of the formula: ##STR1## wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are each a hydrogen atom or a C.sub.1 -C.sub.3 alkyl group and is characteristic in having high stability even after administered into a human body.